The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Antimesothelin vaccine CRS-207 plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM).
Raffit Hassan
No relevant relationships to disclose
Evan W. Alley
No relevant relationships to disclose
Hedy Lee Kindler
No relevant relationships to disclose
Scott Joseph Antonia
No relevant relationships to disclose
Thierry Marie Jahan
No relevant relationships to disclose
Mona Jacobs-Small
No relevant relationships to disclose
Jennifer Hull
No relevant relationships to disclose
Katherine McDougall
Employment or Leadership Position - Aduro Biotech
Stock Ownership - Aduro Biotech
Ed Lemmens
Employment or Leadership Position - Aduro Biotech
Stock Ownership - Aduro Biotech
Aimee Murphy
Employment or Leadership Position - Aduro Biotech
Stock Ownership - Aduro Biotech
John J. Grous
Employment or Leadership Position - Aduro Biotech
Stock Ownership - Aduro Biotech
Thomas Dubensky
Employment or Leadership Position - Aduro Biotech
Stock Ownership - Aduro Biotech
Dirk G. Brockstedt
Employment or Leadership Position - Aduro Biotech
Stock Ownership - Aduro Biotech